Invention Grant
- Patent Title: Fused pentacyclic imidazole derivatives as modulators of TNF activity
-
Application No.: US17284950Application Date: 2019-10-23
-
Publication No.: US11554122B2Publication Date: 2023-01-17
- Inventor: James Andrew Johnson , Ellen Olivia Gallimore , Mengyang Xuan
- Applicant: UCB Biopharma SRL , SANOFI
- Applicant Address: BE Brussels; FR Paris
- Assignee: UCB Biopharma SRL,SANOFI
- Current Assignee: UCB Biopharma SRL,SANOFI
- Current Assignee Address: BE Brussels; FR Paris
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: EP18275165 20181024
- International Application: PCT/EP2019/078922 WO 20191023
- International Announcement: WO2020/084008 WO 20200430
- Main IPC: A61K31/55
- IPC: A61K31/55 ; C07D471/18 ; C07D487/18

Abstract:
A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF a activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20210361668A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity Public/Granted day:2021-11-25
Information query